Research progress on hydrogel-based drug therapy in melanoma immunotherapy

• Published in: BMB reports Vol. 57; no. 2; pp. 71 - 78
• Main Authors: He, Wei, Zhang, Yanqin, Qu, Yi, Liu, Mengmeng, Li, Guodong, Pan, Luxiang, Xu, Xinyao, Shi, Gege, Hao, Qiang, Liu, Fen, Gao, Yuan
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society for Biochemistry and Molecular Biology 01.02.2024; 생화학분자생물학회
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Contributed Mini Review; Drug Delivery Systems; Humans; Hydrogels; Immunotherapy; Melanoma - drug therapy; 화학
• ISSN: 1976-6696; 1976-670X
• DOI: 10.5483/BMBRep.2023-0160

Melanoma is one of the most aggressive skin tumors, and conventional treatment modalities are not effective in treating advanced melanoma. Although immunotherapy is an effective treatment for melanoma, it has disadvantages, such as a poor response rate and serious systemic immune-related toxic side effects. The main solution to this problem is the use of biological materials such as hydrogels to reduce these side effects and amplify the immune killing effect against tumor cells. Hydrogels have great advantages as local slow-release drug carriers, including the ability to deliver antitumor drugs directly to the tumor site, enhance the local drug concentration in tumor tissue, reduce systemic drug distribution and exhibit good degradability. Despite these advantages, there has been limited research on the application of hydrogels in melanoma treatment. Therefore, this article provides a comprehensive review of the potential application of hydrogels in melanoma immunotherapy. Hydrogels can serve as carriers for sustained drug delivery, enabling the targeted and localized delivery of drugs with minimal systemic side effects. This approach has the potential to improve the efficacy of immunotherapy for melanoma. Thus, the use of hydrogels as drug delivery vehicles for melanoma immunotherapy has great potential and warrants further exploration. [BMB Reports 2024; 57(2): 71-78].